The company is developing and making specialized medicines for treating multiple sclerosis, dermatological disorders, female health concerns, cancer and is creating new diagnostic imaging techniques. Berlex, Inc. is a pioneer in the imaging market. It has introduced a broad range of imaging agents. Its contribution began in 1988 with the introduction of the world's first magnetic resonance imaging agent, Magnevist® (gadopentetate dimeglumine) injection. Berlex is headquartered in New Jersey and the U.S. affiliate of Bayer Schering Pharma AG, Germany.

Biliscopin® Infusion, an iodinated contrast medium for intravenous cholecystography is secreted actively by the hepatocytes. The biliary excretion rate of a biliary contrast medium is determined by the binding to plasma proteins and liver receptor proteins, and by its transport maximum for the liver. Because of its high hepatocellular transport rate, Biliscopin® Infusion leads rapidly to high grade contrast density in the intra-hepatic and extra-hepatic biliary ducts as well as in the gallbladder.
Computed tomography with biliary contrast agents provides maximum quality preoperative imaging of the biliary tract.

Cheetah® is a barium sulfate suspension for use as an aid for computed tomography of the gastrointestinal tract. The contrast medium contains additional pineapple-banana flavor suspending agents, simethicone, potassium sorbate, citric acid, sorbitol, artificial sweetener and water. Individual technique will determine the suspension quantity and specific procedure used. For computed tomography of the upper gastrointestinal tract should the patient drink 200-300 mL Cheetah® approximately 30-45 minutes before and an additional 200-300 mL approximately 5-10 minutes prior to the CT scan.
For total bowel opacification an additional 250-450 mL dose of Cheetah® may be given the evening before the examination. Approximately 1-2 hours before the examination should the patient drink 250-450 mL and 5-10 minutes before the CT scan another 250-450 mL. If rapid transit is desired, the suspension can be administered chilled. Rectally use of the contrast agent should be at room temperature to body temperature.

Cholografin® Meglumine is a contrast agent for intravenous cholangiography and cholecystography. Iodipamide's primary excretion through the hepato-biliary system and concentration in bile allows visualization of the gallbladder and biliary ducts.

A clinical trial is a controlled study involving human subjects, designed to evaluate prospectively the safety and effectiveness of new drugs or devices or of behavioral interventions.

See also Adverse Reaction and Safety of Contrast Agents.